Entrada Therapeutics, Inc. (TRDA)
$7.00-$0.27 (-3.71%) Today
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 15 | 576,442 | $4.05M |
| Grant or award | 6 | 114,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
46 Form 4 filings on record, the earliest from Oct 18, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nathan J. Dowden - Officer | Tax withholding / forfeiture | Common Stock | 1,746 | $5.43 | $9K | |
| Kory James Wentworth - Officer | Tax withholding / forfeiture | Common Stock | 1,734 | $5.43 | $9K | |
| 5AM Ventures V, L.P. | Open-market sale | Common Stock | 20,065 | $7.50 | $151K | |
| 5AM Ventures V, L.P. | Open-market sale | Common Stock | 6,935 | $7.50 | $52K | |
| Kush Parmar | Open-market sale | Common Stock | 20,065 | $7.50 | $151K | |
| Kush Parmar | Open-market sale | Common Stock | 6,935 | $7.50 | $52K | |
| 5AM Ventures V, L.P. | Open-market sale | Common Stock | 55,735 | $6.91 | $385K | |
| 5AM Ventures V, L.P. | Open-market sale | Common Stock | 19,265 | $6.91 | $133K | |
| 5AM Ventures V, L.P. | Open-market sale | Common Stock | 18,578 | $6.81 | $127K | |
| 5AM Ventures V, L.P. | Open-market sale | Common Stock | 6,422 | $6.81 | $44K | |
| 5AM Ventures V, L.P. | Open-market sale | Common Stock | 18,578 | $7.12 | $132K | |
| 5AM Ventures V, L.P. | Open-market sale | Common Stock | 6,422 | $7.12 | $46K | |
| Kush Parmar | Open-market sale | Common Stock | 55,735 | $6.91 | $385K | |
| Kush Parmar | Open-market sale | Common Stock | 19,265 | $6.91 | $133K | |
| Kush Parmar | Open-market sale | Common Stock | 18,578 | $6.81 | $127K | |
| Kush Parmar | Open-market sale | Common Stock | 6,422 | $6.81 | $44K | |
| Kush Parmar | Open-market sale | Common Stock | 18,578 | $7.12 | $132K | |
| Kush Parmar | Open-market sale | Common Stock | 6,422 | $7.12 | $46K | |
| Peter S. Kim - Director | Open-market purchase | Common Stock | 25,000 | $14.68 | $367K | |
| Peter S. Kim - Director | Open-market purchase | Common Stock | 25,000 | $14.59 | $365K | |
| Peter S. Kim - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| MPM BioVentures 2014, L.P. | Open-market sale | Common Stock | 22,935 | $20.77 | $476K | |
| MPM BioVentures 2014, L.P. | Open-market sale | Common Stock | 21,787 | $20.23 | $441K | |
| MPM BIOVENTURES 2018, L.P. | Open-market sale | Common Stock | 22,935 | $20.77 | $476K | |
| MPM BIOVENTURES 2018, L.P. | Open-market sale | Common Stock | 21,787 | $20.23 | $441K | |
| Kory James Wentworth - Officer | Option exercise | Common Stock | 1,000 | $2.10 | $2K | |
| Kory James Wentworth - Officer | Open-market sale | Common Stock | 1,000 | $19.97 | $20K | |
| Kory James Wentworth - Officer | Option exercise | Common Stock | 5,000 | $2.10 | $11K | |
| Kory James Wentworth - Officer | Open-market sale | Common Stock | 5,000 | $20.00 | $100K | |
| Kory James Wentworth - Officer | Option exercise | Stock Option (Right to Buy) | 1,000 | $0.00 | - | |
| Kory James Wentworth - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 100 | $20.00 | $2K | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 4,088 | $20.26 | $83K | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 11,703 | $20.15 | $236K | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 1,409 | $20.01 | $28K | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 2,700 | $20.04 | $54K | |
| Kory James Wentworth - Officer | Option exercise | Common Stock | 6,000 | $2.10 | $13K | |
| Kory James Wentworth - Officer | Open-market sale | Common Stock | 8,637 | $19.98 | $173K | |
| Kory James Wentworth - Officer | Option exercise | Stock Option (Right to Buy) | 6,000 | $0.00 | - | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 749 | $18.02 | $13K | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 5,171 | $18.18 | $94K | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 9,554 | $18.71 | $179K | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 2,745 | $19.32 | $53K | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 600 | $18.00 | $11K |
This is as far as the anonymous view goes. Create a free account for all 46 TRDA filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| 5AM Ventures V, L.P. | Affiliated stockholder | 165,578 | $1.08M | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Entrada Therapeutics, Inc. (TRDA) had 12 insider filings in the last 90 days, with the most recent on 2026-08-27. The full record for TRDA runs to 46 Form 4 filings, the earliest from 2024-10-18. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TRDA were filed in the last 90 days. 19 purchases are on record for this company.
15 insider sales of TRDA were filed in the last 90 days, totaling $4.05M.
This page tracks TRDA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TRDA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
